Articles tagged with Androgen Signaling
A new genetic discovery has identified a significant gene called miR137 that is switched off in prostate cancer cells, contributing to the disease's initiation and progression. The study also identified potential targets for next-generation drugs to treat prostate cancer.
Researchers identified a key mechanism driving prostate cancer development, where normal cells undergo epigenetic reprogramming to form malignant growth. The study provides insights into the origins of prostate cancer and potential targets for prevention and treatment.
Research reveals that blocking androgen receptors can reduce the growth of estrogen-positive breast cancers and kill triple-negative breast cancer cells. Combining these drugs with HER2 or mTOR-targeting therapies shows promise for increased effectiveness in treating breast cancer.
A new study found that fracking chemicals can block the activity of key hormone receptors, including glucocorticoid and thyroid hormone receptors. This disruption has been associated with poor health outcomes such as infertility, cancer, and birth defects.
A new study shows that even triple negative breast cancers with low androgen receptor expression can benefit from anti-androgen receptor therapy. The treatment, which targets the androgen receptor, was found to increase programmed cell death, inhibit growth, and increase necrosis in animal models.
Researchers discovered that the androgen receptor may play a crucial role in treating estrogen receptor-positive breast cancer. The study found that women with high levels of androgen receptors were more likely to experience cancer recurrence during tamoxifen treatment.
Researchers at Michigan Medicine have found that BET bromodomain protein 4 binds to the hormone androgen receptor, making it a potential target for prostate cancer treatment. The study suggests that a drug targeting this protein could work even when prostate cancer becomes resistant to current therapies.
A collaborative study identifies PRNCR1 and PCGEM1 as long non-coding RNAs that activate androgen receptors, leading to cancer growth and resistance to treatment. The study provides a new target for therapies and offers hope for developing more effective treatments for aggressive prostate cancer.
Scientists use antigen-decorated nanoparticles to prevent immune over-reaction in mice, while also developing a potential gene therapy for Mucopolysaccharidosis Type IIIA. Meanwhile, researchers discover a new target for castration-resistant prostate cancer by blocking mutant androgen receptors.
Researchers developed a novel class of peptidomimetic drugs that interrupt androgen receptor signaling in prostate cancer cells, preventing growth. The agents show promise as a potential therapeutic approach for men with advanced disease.
A novel small molecule has been developed to block the function of androgen receptors, which promote prostate cancer growth. The compound prevents cancer cells from recruiting protein partners and blocks their growth, showing promise for treating prostate cancer.
A study by Sanford-Burnham researchers found that Siah2 keeps androgen receptors constantly active in prostate cancer cells, enabling them to survive treatment. Inhibiting Siah2 may provide a new method for re-sensitizing castration-resistant prostate tumors to hormone therapy.
Researchers developed a noninvasive assay to monitor treatment response in patients with metastatic prostate cancer. The assay measures androgen receptor signaling pathway activity in circulating tumor cells, allowing for early detection of resistance to treatment.
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
Researchers have identified androgen receptors as a key target for treating breast cancer, leading to the development of enzalutamide as a potential new therapy. The study suggests that blocking these receptors can inhibit cancer growth, offering new hope for patients with hormone-dependent breast cancers.
Researchers found 22% of TNBC patients had the androgen receptor, which was linked to more aggressive cancer but not necessarily worse survival rates. The study suggests targeting the androgen receptor could be a new way to treat TNBC.
Researchers at LSU Health Sciences Center have identified a new protein called ARD1 that plays a critical role in the development and growth of prostate cancer. Inactivating this protein completely suppresses cancer growth, making it a potential target for new treatments.
Scientists at Dana-Farber Cancer Institute have identified a novel subtype of breast cancer that grows in response to androgen but not estrogen. The study reveals the signaling pathways involved in its growth and demonstrates that drugs capable of blocking these pathways can inhibit tumor growth.
A recent study by UNC researchers provides evidence that a specific gene, MAGE-11, interacts with proteins to promote androgen receptor activity in advanced prostate cancer cells. This finding opens the door to additional targets for new therapies and broader clinical applications of new drugs.
A new study reveals that male sex hormones play a crucial role in regulating female fertility by controlling follicle growth and development. The research suggests that irregular levels of these hormones can lead to infertility, especially in women with polycystic ovarian syndrome.
A University of Rochester study found a direct link between the androgen receptor and hepatitis B virus in causing liver cancer, explaining why men get the disease more often than women. Researchers showed that targeting the androgen receptor could lead to new treatment approaches for patients with hepatocellular carcinoma.
A new study found that gene fusions are a specific 'bad actor' in prostate cancer and should be targeted by treatments, rather than the androgen receptor. The research suggests that blocking these fusions can prevent normal prostate cell development, allowing cancer to develop.
Researchers at Van Andel Research Institute have identified key proteins involved in the development of prostate cancer. Understanding their interaction could lead to more effective treatments by targeting this molecular link.
The androgen receptor, crucial for male hormones like testosterone, also plays a significant role in the body's ability to heal wounds. Blocking this receptor accelerates wound healing by reducing inflammation.
Chromosomal translocations, a hallmark of leukemias and lymphomas, may be more systematically driven than previously thought. The study identifies the male sex hormone (androgen) receptor as a key player in driving specific translocations in prostate cancer.
Researchers discover how androgen receptor switches to a new set of genes, leading to increased cell division and tumor progression. This finding may lead to the development of gene-targeted therapies to shut down the alternate growth program.
Researchers at Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveal how late-stage prostate tumors gain ability to grow without hormones. The study identifies a gene called UBE2C as key regulator in hormone-independent growth.
Researchers found a protein, βarrestin2, that suppresses androgen receptor expression in prostate cancer cells, potentially halting disease progression. Increased levels of βarrestin2 may lead to improved staging and treatment of testosterone-fueled prostate cancer.
Researchers at Baylor College of Medicine have developed a new high throughput microscopy technique that enables analysis of hormone receptors on a cell-by-cell basis. This allows for personalized medicine applications, such as identifying the most effective drug treatments for mutated cells.
Researchers have found that a common treatment for advanced prostate cancer can actually cause some cancer cells to grow, rather than stopping them. The androgen receptor plays a versatile role in the disease, acting as both a tumor promoter and suppressor in different cell types.
Researchers at UCLA's Jonsson Cancer Center found that hormone refractory prostate cancers are more invasive and likely to spread to other organs than androgen-dependent cancers. The study suggests that blocking overexpression of the androgen receptor could prevent cancer spread.
Researchers found that the androgen receptor plays a key role in bladder cancer development, which explains why it affects men more than women. The discovery opens doors to new treatment options and may help doctors predict tumor recurrence.
Testicular cancer survivors have a higher risk of dying from noncancer causes, including infections and circulatory diseases. Chemotherapy treatment in the 1970s also increases this risk. Researchers highlight the need for additional long-term follow-up studies to better understand secondary complications.
Cancer researchers have identified a promising compound, ASC-J9, that slows the progression of Kennedy's disease in mice carrying the mutant human gene. The compound breaks up a molecular clog in neurons affected by the disease, improving mobility and muscle function.
Thomas Jefferson University researchers have found a connection between an aging gene and the prevention of prostate cancer cell growth. The study reveals that SIRT1, a sirtuin enzyme, can block cancer growth by inhibiting the activity of mutated androgen receptors, which are resistant to current therapies.
A novel computational model predicts androgen receptor binding sites in the prostate cancer genome. Experimental verification confirms the accuracy of the model, providing new insights into prostate cancer biology.
A genetic variant of the androgen receptor gene has been found to be associated with premature balding in men, leading to more androgen receptors in the scalp. The findings suggest that this genetic defect can be inherited from the mother and may also involve other genes.
Researchers discovered that certain mutations in the androgen receptor cause advanced prostate cancer when introduced into healthy mice. These findings shed light on why hormone withdrawal therapy fails to cure most men with advanced prostate cancer, and open the door to discovering new, effective therapies.
A four-year project aims to understand how androgen influences the skeleton, with potential implications for stress fracture prevention and treating osteoporosis. The study examines the effects of androgen therapy on bone health in both men and women.
Researchers discovered that the HER2/ERBB3 pathway regulates androgen receptor function, contradicting previous beliefs about EGFR's role. This finding may explain limited success of Gefitinib, an EGFR inhibitor, in treating hormone-refractory prostate cancer.
Researchers found that the normal form of the BRCA-2 gene enhances androgen receptors' activity to suppress tumors. The mutant form of BRCA-2 fails to enhance activity, allowing cancer cells to proliferate. The study provides new insights into male breast cancer and its connection to the BRCA-2 gene.
A team of Dutch doctors and scientists have found a possible link between testosterone and endometrial cancer, with high local pelvic androgen levels and increased expression of androgen receptors detected in patients. The study suggests that androgens may be a co-factor in the development of endometrial cancer.
Scientists at Duke University discovered a genetic switch that governs prostate cancer progression. The switch controls the production of FGF-R2 receptors, which can lead to
A new study found that steroid receptors are not mere on-off switches but rather complex molecular control panels. This discovery could lead to the development of targeted therapies for various diseases such as breast and prostate cancer, inflammation, osteoporosis, and endometriosis.